ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry"

  • Abstract Number: 0306 • ACR Convergence 2022

    Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry

    Gabriela Schmajuk1, Nevin Hammam2, Jing Li3, David Collier4, Greg Kricorian5 and Scott Stryker6, 1UCSF / SFVA, San Francisco, CA, 2Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, 3University of California, San Francisco, San Francisco, CA, 4Amgen Inc., Simi Valley, CA, 5Amgen, Inc., Thousand Oaks, CA, 6Amgen Inc., San Francisco, CA

    Background/Purpose: Data regarding the maintenance of disease activity (DA) and treatment persistence in patients (pts) who switched from combination therapy to monotherapy for the management…
  • Abstract Number: 1423 • ACR Convergence 2022

    Long-Term Treatment with Golimumab Is a Safe Treatment Option Regardless of Risk Factors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting

    Regan Arendse1, Proton Rahman2, Philip Baer3, Derek Haaland4, Dalton Sholter5, Odalis Asin-Milan6, Meagan Rachich7, Emmanouil Rampakakis8, A. Marilise Marrache9 and Allen J. Lehman10, 1Community Rheumatology Care, Saskatoon, Canada, 2Memorial University, St. John's, NL, Canada, 3Baer Weinberg MPC, Scarborough, ON, Canada, 4The Waterside Clinic, Oro Medonte, ON, Canada, 5University of Alberta, Edmonton, AB, Canada, 6Janssen Canada, Laval, QC, Canada, 7Janssen Inc., Guelph, ON, Canada, 8McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 9Janssen Inc., Dollard-des-Ormeaux, QC, Canada, 10Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Golimumab (GLM), a tumor necrosis factor inhibitor (TNFi), has demonstrated efficacy and a favorable safety profile in inflammatory rheumatic diseases. Recent safety studies with…
  • Abstract Number: 0350 • ACR Convergence 2022

    Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus

    Vicente Aldasoro1, María Laiño1, Monica Enguita1, Santos Castañeda2, Javier Loricera3, Carmen Lasa-Teja4, Clara Moriano5, Vanesa Calvo Río6, Ivette Casafont-Solé7, Judit Font Urgelles7, Patricia Quiroga-Colina8, Samuel Hernandez9, Sergi Heredia10, A. Garcia-Aparicio11, Joaquin Maria Belzunegui Otano12, Aaron Fariña13, Francisco Javier Navarro Blasco14, Patricia Fanlo Mateo1, Adela Gallego15, Juan M Blanco Madrigal16, María Ángeles Matías17, Cilia Peralta18, Jordi Camins-Fàbregas19, Marcos Paulino20, Ana Urruticoechea21, Piter Jose Cossio Jimenez22, Miguel Medina Malone23, Eva Perez Pampin24, Rafaela Ortega-Castro25, Blanca varas de Dios26, Jose Ramon Lamua Riazuelo27 and Emilio Jose Giner28, 1Hospital Universitario de Navarra, Pamplona, Spain, 2Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 3Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Complejo Asistencial Universitario de León, León, Spain, 6Valdecilla Hospital, Santander, Spain, 7Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 8Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 9Hospital Son Llàtzer, Palma de Mallorca, Spain, 10Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despi, Spain, 11Hospital Universitario de Toledo, Toledo, Spain, 12Hospital Universitario de Donostia, Donostia-San Sebasti, Spain, 13Complejo Asistencial Universitario de Palencia, Palencia, Spain, 14Hospital General Universitario de Elche, Elche, Spain, 15Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 16Basurto University Hospital, Bilbao, Spain, 17Hospital Universitario Infanta Leonor, Madrid, Spain, 18Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 19Hospital General de Granollers, Granollers, Spain, 20Hospital General Universiario de Ciudad Real, Ciudad Real, Spain, 21Hospital Can Misses, Ibiza, Spain, 22Hospital Reina Sofia, Tudela, Spain, 23Hospital Calahorra, Calahorra, Spain, 24Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Cordoba, Spain, 25IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 26Santa Cristina Hospital, Madrid, Spain, 27Hospital Universitario del Henares, Madrid, Spain, 28Hospital Royo Villanova, Zaragoza, Spain

    Background/Purpose: To describe demographic characteristics, efficacy and safety of BLM since its approval in SLE patients in a real-world setting. Methods: Descriptive, retrospective, multicenter study…
  • Abstract Number: 1431 • ACR Convergence 2022

    Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis

    Karen E Hansen1, Mahta Mortezavi2, Edward Nagy3, Cunshan Wang4, Carol A Connell4, Zaher Radi5, Heather J Litman6, Giovanni Adami7 and Maurizio Rossini7, 1Rheumatology Division, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 2Pfizer Inc, New York, NY, 3Pfizer Ltd, Tadworth, United Kingdom, 4Pfizer Inc, Groton, CT, 5Pfizer Inc., Cambridge, MA, 6CorEvitas, LLC, Waltham, MA, 7Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy

    Background/Purpose: Preclinical data suggest that tofacitinib stimulates osteoblast function and would have a protective effect on bone health and fracture risk in RA.1 We report…
  • Abstract Number: 0422 • ACR Convergence 2022

    Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort

    Semih Gulle1, Ali Karakas1, Gercek Can2, Soner Senel3, Sedat Capar4, Huseyin ediz dalkilic5, Servet Akar6, Suleyman Serdar Koca7, Abdurrahman Tufan8, Ayten Yazici9, Sema Yilmaz10, Nevsun Inanc11, Merih Birlik1, Dilek Solmaz12, Ayse Cefle9, Berna Goker13, Servet Yolbas14, Niels Steen Krough15, Neslihan Yilmaz16, Sukran Erten17, Cemal Bes18, Ozgul Soysal19, Mehmet Akif Ozturk13, Seminur Haznedaroglu13, Sule Yavuz16, Haner Direskeneli20, Fatoş Onen21 and Ismail Sari22, 1Dokuz Eylul University School of Medicine Division of Rheumatology, Izmir, Turkey, 2Dokuz Eylul University School of Medicine Division of Rheumatology, Istanbul, Turkey, 3Erciyes University School of Medicine Division of Rheumatology, Kayseri, Turkey, 4Dokuz Eylul University Faculty of Science Department of Statistics, Izmir, Turkey, 5Uludag University School of Medicine Division of Rheumatology, Bursa, Turkey, 6Izmir Katip Celebi University School of Medicine, Izmir, Turkey, 7Firat University School of Medicine Division of Rheumatology, Elazıg, Turkey, 8Gazi University Medical Faculty Hospital, Istanbul, Turkey, 9Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, 10Selcuk University School of Medicine Division of Rheumatology, Konya, Turkey, 11Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, 12Kâtip Celebi University School of Medicine Division of Rheumatology, Izmir, Turkey, 13Gazi University School of Medicine Division of Rheumatology, Ankara, Turkey, 14Inonu University School of Medicine Division of Rheumatology, Malatya, Turkey, 15Zitelab Aps, Kopenhag, Denmark, 16Demiroglu Bilim University School of Medicine Division of Rheumatology, Istanbul, Turkey, 17Yildirim Beyazit University School of Medicine Division of Rheumatology, Ankara, Turkey, 18Basaksehir Cam and Sakura ospital, Division of Rheumatology, Istanbul, Turkey, 19Celal Bayar University, School of Medicine Division of Rheumatology, Manisa, Turkey, 20Marmara University School of Medicine Division of Rheumatology, Istanbul, Turkey, 21Dokuz Eylul University, Faculty of Medicine, Rheumatology, İzmir, Turkey, 22Dokuz Eylul University School of Medicine Division of Rheumatology, İzmir, Turkey

    Background/Purpose: In this study, we aimed to evaluate the results of secukinumab treatment in patients with Axial Spondyloarthritis (AxSpA) who were enrolled in the TURKBIO…
  • Abstract Number: 1522 • ACR Convergence 2022

    The Collaborative National Quality and Efficacy Registry for Scleroderma: Association of Medication Use on Gastrointestinal Tract Symptoms in Early Disease

    Sarah Luebker1, Tracy Frech1, Shervin Assassi2, Jessica Gordon3, Elana Bernstein4, Virginia Steen5, Ami Shah6, Laura Hummers7, Carrie Richardson8, Dinesh Khanna9, Flavia Castelino10, Lorinda Chung11, Faye Hant12, Vicki Shanmugam13, John VanBuren14, Jessica Alvey14, Monica Harding14, Luke Evnin15 and Nora Sandorfi16, 1Vanderbilt University Medical Center, Nashville, TN, 2McGovern Medical School, University of Texas, Houston, TX, 3Hospital for Special Surgery, New York, NY, 4Columbia University, New York, NY, 5Georgetown University School of Medicine, Washington, DC, 6Johns Hopkins Rheumatology, Baltimore, MD, 7Johns Hopkins Univerisity, Baltimore, MD, 8Northwestern University, Chicago, IL, 9Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 10Massachusetts General Hospital, Boston, MA, 11Stanford University, Stanford, CA, 12Medical University of South Carolina, Charleston, SC, 13George Washington University, Washington, DC, 14University of Utah, Salt Lake City, UT, 15Scleroderma Research Foundation, Brisbane, CA, 16University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Gastrointestinal tract (GIT) symptoms are common amongst systemic sclerosis (SSc) patients.1 The Scleroderma Clinical Trials Consortium University of California Los Angeles Gastrointestinal Tract Questionnaire…
  • Abstract Number: 0433 • ACR Convergence 2022

    Clustering of Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis – Using a Pre-processed Harmonised Dataset

    Karl Gisslander1, Arthur White2, Mårten Segelmark3, Mark Little2 and Aladdin Mohammad4, 1Lund University, Lund, Sweden, 2Trinity College, Dublin, Ireland, 3Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, 4Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden

    Background/Purpose: The sub-classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has been a long-standing debate. Unsupervised learning has previously been used for partitioning of phenotypic…
  • Abstract Number: 1679 • ACR Convergence 2022

    The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes

    Yukiko Kimura1, Sarah Ringold2, George Tomlinson3, Laura Schanberg4, Anne Dennos5, MaryEllen Riordan6, Vincent Del Gaizo7, Katherine Murphy8, Pamela Weiss9, Brian Feldman10, Mei Sing Ong11 and Marc Natter12, 1Hackensack Meridian Health, New York, NY, 2Janssen, Seattle, WA, 3University of Toronto, Toronto, ON, Canada, 4Duke University Medical Center, Durham, NC, 5Duke University, Durham, NC, 6Hackensack Meridian Health, Hackensack, NJ, 7CARRA, Inc, Washington, DC, 8CARRA, Inc, New Orleans, LA, 9Children's Hospital of Philadelphia, Glen Mills, PA, 10Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 11Harvard Pilgrim Institute, Boston, MA, 12Boston Children's Hospital, Boston, MA

    Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinically inactive disease (CID) in untreated polyarticular JIA…
  • Abstract Number: 0820 • ACR Convergence 2022

    Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study

    Diala Alawneh1, Moustafa Younis2, Bashar Alzghoul2, Christian Ascoli1, Tricha Shivas3, Mary McGowan3, Khaldoon Alawneh4, Divya Patel2, Israel Rubinstein1 and Nadera Sweiss1, 1University of Illinois at Chicago, Chicago, IL, 2University of Florida, Gainesville, FL, 3Foundation for Sarcoidosis Research, Chicago, IL, 4Jordan University of Science and Technology, Irbid, Jordan

    Background/Purpose: Chronic arthropathy is a rare manifestation of sarcoidosis reported in only 0.2% of patients. However, treatment is challenging because no general consensus regarding appropriate…
  • Abstract Number: 1752 • ACR Convergence 2022

    Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER

    Isabel Castrejon1, Juan Molina2, Carolina Perez-Garcia3, Paloma Vela-Casampere4, Cesar Diaz-Torne5, Cristina Bohorquez6, Juan Maria Blanco-Madrigal7 and Fernando Sanchez-Alonso8, 1Hospital Universitario Gregorio Marañón, Madrid, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Department of Rheumatology, Hospital del Mar, Barcelona, Spain, 4Hospital General Universitario Alicante, Alicante, Spain, 5Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 6University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain, 7Department of Rheumatology, Hospital de Basurto, Bilbao, Spain, 8Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

    Background/Purpose: Extensive evidence has confirmed no increased risk of cancer associated to either conventional synthetic DMARDs or anti-TNF in patients with rheumatic diseases. The risk…
  • Abstract Number: 0850 • ACR Convergence 2022

    Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry

    Melissa Mannion1, Shahla Amin2, Stephen Balevic3, Colleen Correll4, Timothy Beukelman1 and , for the CARRA Registry Investigators5, 1University of Alabama at Birmingham, Birmingham, AL, 2Childhood Arthritis and Rheumatology Research Alliance, Washington, DC, 3Duke University, Durham, NC, 4University of Minnesota, Minneapolis, MN, 5CARRA, Washington, DC

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are the most commonly used first biologics to treat juvenile idiopathic arthritis (JIA), but it is unknown what subsequent…
  • Abstract Number: 1842 • ACR Convergence 2022

    Vaccination in Patients with Autoinflammatory Periodic Syndromes Under Canakinumab – Safety Data Interim Analysis of the RELIANCE Registry

    Jasmin B. Kuemmerle-Deschner1, Joerg Henes2, Birgit Kortus-Goetze3, Tilmann Kallinich4, Prasad T. Oommen5, Juergen Rech6, Tobias Krickau7, Frank Weller-Heinemann8, Gerd Horneff9, Ales Janda10, Ivan Foeldvari11, Catharina Schuetz12, Frank Dressler13, Michael Borte14, Markus Hufnagel15, Florian Meier16, Michael Fiene17, Julia Weber-Arden18 and Norbert Blank19, 1Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, 2Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, 3Division of Nephrology, University of Marburg, Marburg, Germany, 4Charité - Universitätsmedizin Berlin, Nuremberg, Germany, 5Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 6University Clinic Erlangen, Erlangen, Germany, 7Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, 8Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, 9Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, 10Department of Pediatrics, University Hospital Ulm, Ulm, Germany, 11Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, 12Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, 13Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, 14ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Sachsen, Germany, 15Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, 16Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, 17Rheumatology Center Greifswald, Greifswald, Germany, 18Novartis Pharma GmbH, Nuernberg, Germany, 19Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

    Background/Purpose: Treatment of autoinflammatory periodic syndromes with the interleukin-1β inhibitor canakinumab (CAN) has been shown to be safe and effective in clinical trials and in…
  • Abstract Number: 0855 • ACR Convergence 2022

    Change in Short Term Outcomes Following Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

    Melissa Mannion1, Fenglong Xie1, Timothy Beukelman1, Jeffrey Curtis2 and , for the CARRA Registry Investigators3, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Hoover, AL, 3CARRA, Washington, DC

    Background/Purpose: Current recommendations suggest treatment escalation for juvenile idiopathic arthritis (JIA) until the disease activity target is reached, ideally inactive or low disease activity. Our…
  • Abstract Number: 1992 • ACR Convergence 2022

    Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry

    Joshua Baker1, J Morel Symons2, Jud C Janak3, Page Moore3, Elizabeth Kohl3, Bernice Gershenson3, Oksana Pugach3, Dave Webb4, Alan A Martin4, Didier Saurigny5 and Marguerite Bracher5, 1University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 2GlaxoSmithKline, Collegeville, PA, 3CorEvitas, LLC, Waltham, MA, 4GlaxoSmithKline, Brentford, United Kingdom, 5GlaxoSmithKline, Stevenage, United Kingdom

    Background/Purpose: Pain is a hallmark symptom of RA that impacts patients' quality of life and informs therapeutic decisions that aim to reduce joint inflammation and…
  • Abstract Number: 0888 • ACR Convergence 2022

    Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT)

    Nathalie Carrier1, Sophie Roux2, Hugues Allard-Chamard2 and Gilles Boire3, 1Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, 2Université de Sherbrooke and Centre intégré universitaire de santé et services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, QC, Canada, 3Universite de Sherbrooke, Sherbrooke, QC, Canada

    Background/Purpose: Uncontrolled inflammation in rheumatoid arthritis (RA) patients increases the risk for incident Ischemic Heart Disease (IHD) and venous thromboembolic (TE) events. Reducing inflammation using…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology